Merck & Co., Inc.: analysis of patenting 1998-2002

被引：0
作者：
Norman, P [1 ]
机构：
[1] Norman Consulting, Burnham SL1 8JW, Bucks, England
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2003年 / 13卷 / 07期
关键词：
patent analysis; pharmaceutical industry;
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
This article complements an earlier (1997) review of the patenting policy of Merck and indicates how the company continues to file extensively. It compares the patenting activity across each major therapeutic area with the company's 2001 revenues from these therapeutic areas.
引用
收藏
页码：1037 / 1044
页数：8
相关论文
共 17 条
  • [1] Orally efficacious NR2B-selective NMDA receptor antagonists
    Claiborne, CF
    McCauley, JA
    Libby, BE
    Curtis, NR
    Diggle, HJ
    Kulagowski, JJ
    Michelson, SR
    Anderson, KD
    Claremon, DA
    Freidinger, RM
    Bednar, RA
    Mosser, SD
    Gaul, SL
    Connolly, TM
    Condra, CL
    Bednar, B
    Stump, GL
    Lynch, JJ
    Macaulay, A
    Wafford, KA
    Koblan, KS
    Liverton, NJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (04) : 697 - 700
  • [2] *CURR PAT LTD, 2001, DRUG PAT 2001 REV PH
  • [3] Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2
    Machwate, M
    Harada, S
    Leu, CT
    Seedor, G
    Labelle, M
    Gallant, M
    Hutchins, S
    Lachance, N
    Sawyer, N
    Slipetz, D
    Metters, KM
    Rodan, SB
    Young, R
    Rodan, GA
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (01) : 36 - 41
  • [4] MERCK CO INC, 2003, Patent No. 03002118
  • [5] MERCK CO INC, 2000, Patent No. 0016626
  • [6] MERCK CO INC, 2002, Patent No. 02060897
  • [7] Pfizer, Inc.: analysis of patenting 1998-2001
    Norman, P
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (05) : 725 - 732
  • [8] GlaxoSmithKline plc: analysis of patenting 1998-2001
    Norman, P
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (09) : 1407 - 1415
  • [9] NORMAN P, 2002, PHARM DEV PIPELINES, pCH8
  • [10] NORMAN P, 2002, EARLY STAGE PHARM DE, pCH12
12